logo
logo
Doximity, Inc.

Doximity, Inc.

NYSE•DOCS
CEO: Mr. Jeffrey A. Tangney
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2021-06-24
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. It primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Contact Information
500 3rd Street, Suite 510, San Francisco, CA, 94107, United States
650-549-4330
www.doximity.com
Market Cap
$4.74B
P/E (TTM)
19.8
27.6
Dividend Yield
--
52W High
$79.97
52W Low
$23.66
52W Range
3%
Rank22Top 8.4%
5.9
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 5.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2026 Data

Revenue

$185.05M+0.00%
4-Quarter Trend

EPS

$0.33+0.00%
4-Quarter Trend

FCF

$62.86M+0.00%
4-Quarter Trend

2026 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Subscription revenue grew 16% to $499.5M for nine months ended December 31, 2025; driven by new customers.
Adjusted EBITDA Strong Adjusted EBITDA reached $292.0M for nine months, marking nearly 20% growth over prior period results.
Solid Net Income Performance Net income totaled $176.9M for nine months, an increase of $16.2M compared to the prior year.
Strong Liquidity Position Total cash and marketable securities stand at $735.1M as of December 31, 2025, supporting operations.

Risk Factors

Securities Lawsuit Settlement Recognized $31M liability for securities lawsuit settlement; derivative lawsuits remain outstanding with uncertain outcomes.
Revenue Retention Rate Decline Net revenue retention rate decreased to 112% as of December 31, 2025, down from 117% last year.
Increased Operating Expenses R&D expenses surged 54% for the quarter due to stock compensation and increases in average headcount.
Contingent Earn-out Liability Contingent earn-out liability decreased to $5.8M, but changes in Level 3 inputs significantly impact fair value.

Outlook

Pathway Acquisition Integration Completed Pathway Medical acquisition in July 2025 for $36.3M to enhance AI knowledge platform capabilities.
Share Repurchase Availability $83.0M remains authorized for Class A common stock repurchase under the existing $500M program.
Future Capital Requirements Future capital needs depend on growth, R&D spending, and potential future acquisitions; financing may be required.
R&D Investment Focus Expect R&D expenses to increase absolutely as engineering teams build new products and improve existing offerings.

Peer Comparison

Revenue (TTM)

Universal Health Services, Inc.UHS
$16.99B
+10.2%
Viatris Inc.VTRS
$14.12B
-6.1%
Baxter International Inc.BAX
$11.24B
+5.7%

Gross Margin (Latest Quarter)

Neurocrine Biosciences, Inc.NBIX
97.8%
-0.5pp
Universal Health Services, Inc.UHS
90.8%
+0.6pp
Doximity, Inc.DOCS
89.9%
+0.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EXAS$19.62B-94.2-8.5%43.0%
VTRS$18.41B-5.0-22.7%38.8%
COO$16.64B44.24.5%22.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
10.2%
Steady Growth
4Q Net Income CAGR
-0.5%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:May 13, 2026
|
EPS:-
|
Revenue:-
Reports
Financials
News
All Years

  • Form 10-Q - Q3 2026

    Period End: Dec 31, 2025|Filed: Feb 5, 2026|
    Revenue: $185.05M+0.0%
    |
    EPS: $0.33+0.0%
    Miss

  • Form 10-Q - Q2 2026

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $168.53M+23.2%
    |
    EPS: $0.33+37.5%
    Miss

  • Form 10-Q - Q1 2026

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $145.91M+15.2%
    |
    EPS: $0.28+27.3%
    Miss

  • Form 10-K - FY 2025

    Period End: Mar 31, 2025|Filed: May 20, 2025|
    Revenue: $570.40M+20.0%
    |
    EPS: $1.19+52.6%
    Beat

  • Form 10-Q - Q3 2025

    Period End: Dec 31, 2024|Filed: Feb 6, 2025|
    Revenue: $168.60M+24.6%
    |
    EPS: $0.40+53.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $136.83M+20.4%
    |
    EPS: $0.24+50.0%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $126.68M+16.8%
    |
    EPS: $0.22+46.7%
    Meet

  • Form 10-K - FY 2024

    Period End: Mar 31, 2024|Filed: May 23, 2024|
    Revenue: $475.42M+13.5%
    |
    EPS: $0.78+34.5%
    Beat